Exact Sciences — Nov 3, 2025 release

The momentum we are building is fueling growth, advancing innovative new tests like Cancerguard, and strengthening our financial performance." Third quarter 2025 financial results For the three-month period ended September 30, 2025, as compared to the same period of 2024 (where applicable): • Total revenue was $851 million, an increase of 20% on a reported and core revenue basis • Screening revenue was $666 million, an increase of 22% • Precision Oncology revenue was $184 million, an increase of 13% • Gross margin was 69%, and adjusted gross margin was 71% • Net loss was $20 million, or $0.10 per share, an improvement of $19 million and $0.10 per share, respectively • Adjusted EBITDA was $135 million, an increase of $37 million or 37%, and adjusted EBITDA margin was 16%, an increase of 200 basis points • Operating cash flow was $220 million and free cash flow was $190 million, an increase of 59% and 69%, respectively, • Cash, cash equivalents, and marketable securities were $1.00 billion at the end of the quarter Screening primarily includes laboratory service revenue from Cologuard® tests and PreventionGenetics. Precision Oncology includes laboratory service revenue from global Oncotype DX® and therapy selection tests. Platform and pipeline advancements In September 2025, Exact Sciences launched its Cancerguard ® multi-cancer early detection (MCED) test as a laboratory-developed test. Cancerguard is the first multi-cancer early detection test commercially available that analyzes multiple biomarker classes to help dete